Branded gastrointestinal drugs dominated the market in 2016. However, it is anticipated to observe a decline
in CAGR during the upcoming period due to saturation of generic medicines in the market. Gastrointestinal
Therapeutics Market may be explored by Route Administration as Intravenous, Oral, and Others. “Intravenous”
segment dominated the route administration in the industry in 2016. Gastrointestinal Therapeutics industry
may be explored by applications as GERD, Ulcerative Colitis, Crohn’s Disease, and others. “Others” segment
dominated the market in 2016. This “others” segment may comprise chronic idiopathic constipation, irritable
bowel syndrome opioid-induced constipation, diarrhea, nausea, recurrent gastrointestinal infections,
gastrointestinal stromal tumor, and pancreatic insufficiency.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market
Gastrointestinal Therapeutics Market may be explored by Distribution Channel as Online Pharmacies, Hospital
Pharmacies, and Retail Pharmacies. The Online pharmacies segment dominated the Gastrointestinal
Therapeutics industry in 2017. Moreover, increasing occurrence of chronic diseases. In addition, growing
incidence of chronic diseases has caused in an extensive gap in the source of and demand for main drugs. The
factors are anticipated to present remunerative development projections for online pharmacies throughout the
upcoming period.
North America accounted for the major share of the global Gastrointestinal Therapeutics Market Size Analysis
in 2016 and will continue to rule the roost in the forecast period. The market for Gastrointestinal Therapeutics
in North America, especially in the U.S., is the most lucrative one and gaining robust traction from numerous
features such as changing lifestyle, resultant in grater occurrence of gastrointestinal diseases will upsurge the
gastrointestinal therapeutics in North America region in the years to come. North America followed by Asia-
Pacific region.
Some of the key players that fuel the growth of the gastrointestinal therapeutics industry include Johnson &
Johnson, Abbott Laboratories, AbbVie Inc., Salix Pharmaceuticals, Pfizer Inc, AstraZeneca, Takeda
Pharmaceutical Company Limited, Astellas Pharma US, Inc., ALLERGAN, and GlaxoSmithKline Plc. The leading
companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the
inorganic growth of the industry.
Market Segment:
Gastrointestinal Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)
• Branded
• Aminosalicylates
• Antacids